For the year ending 2025-12-31, SPRY has $327,652K in assets. $213,394K in debts. $41,317K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 41,317 | |||
| Short-term investments | 203,669 | |||
| Accounts receivable, net | 25,347 | |||
| Inventories | 8,369 | |||
| Prepaid expenses and other current assets | 6,194 | |||
| Total current assets | 284,896 | |||
| Inventories, noncurrent | 23,053 | |||
| Property, plant and equipment, net | 2,465 | |||
| Intangible assets, net | 14,452 | |||
| Other assets | 2,786 | |||
| Total assets | 327,652 | |||
| Accounts payable and accrued liabilities (including related party amounts of 1,624 and 656, respectively) | 37,948 | |||
| Contract liability, current | 609 | |||
| Other current liabilities | 588 | |||
| Total current liabilities | 39,145 | |||
| Term loans, net (including related party amounts of 4,819 and 0, respectively) | 96,374 | |||
| Financing liability | 72,140 | |||
| Contract liability, net of current portion | 1,130 | |||
| Other accrued liabilities | 4,605 | |||
| Total liabilities | 213,394 | |||
| Common stock, 0.0001 par value per share 200,000,000 shares authorized at december 31, 2025 and 2024 99,290,926 and 97,954,172 shares issued and outstanding at december 31, 2025 and 2024, respectively | 10 | |||
| Additionalpaid-incapital | 408,726 | |||
| Accumulated other comprehensive gain, net | 125 | |||
| Accumulated deficit | -294,603 | |||
| Total stockholders' equity | 114,258 | |||
| Total liabilities and stockholders' equity | 327,652 | |||
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)